Impact of gene patents and licensing practices on access to genetic testing for hearing loss.
Genetic testing for heritable hearing loss involves a mix of patented and unpatented genes, mutations and testing methods. More than half of all hearing loss is linked to inherited mutations, and five genes are most commonly tested for in the United States. There are no patents on three of these genes, but Athena Diagnostics holds exclusive licenses to test for a common mutation in the GJB2 gene associated with about 50% of all cases as well as mutations in the MTRNR1 gene. This fragmented intellectual property landscape made hearing loss a useful case study to assess whether patent rights in genetic testing can proliferate or overlap, and whether it is possible to gather the rights necessary to perform testing. Testing for hearing loss is widely available, primarily from academic medical centers. Based on literature reviews and interviews with researchers, research on the genetics of hearing loss has generally not been impeded by patents. There is no consistent evidence of a premium in testing prices attributable to patent status. Athena Diagnostics has, however, used its intellectual property to discourage other providers from offering some tests. There is no definitive answer about the suitability of current patenting and licensing of commonly tested genes because of continuing legal uncertainty about the extent of enforcement of patent rights. Clinicians have also expressed concerns that multiplex tests will be difficult to develop because of overlapping intellectual property and conflict with Athena's sole provider business model.
Chandrasekharan
Subhashini
S
Center for Public Genomics, Center for Genome Ethics, Law and Policy, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA. shubha.c@duke.edu
Fiffer
Melissa
M
D000072259:Connexin 26; D017630:Connexins / Q000235:genetics; D005796:Genes; D005820:Genetic Testing; D006297:Health Services Accessibility; D034381:Hearing Loss / Q000175:diagnosis* / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D008004:Licensure; D009154:Mutation; D010330:Patents as Topic; D017410:Practice Guidelines as Topic; D012335:RNA, Ribosomal / Q000235:genetics
D017630:Connexins; C000607042:GJB2 protein, human; D012335:RNA, Ribosomal; C075526:RNA, ribosomal, 12S; D000072259:Connexin 26
Hum Mutat. 1994;3(3):243-7
8019558
Am J Hum Genet. 2003 Dec;73(6):1452-8
14571368
N Engl J Med. 2002 Jan 24;346(4):243-9
11807148
Ear Hear. 2006 Dec;27(6):628-44
17086075
Am J Med Genet A. 2004 Sep 15;130A(1):29-36
15368492
Genet Test. 2003 Spring;7(1):49-56
12820703
J Mol Diagn. 2006 Sep;8(4):483-9; quiz 528
16931589
Science. 1998 May 1;280(5364):698-701
9563938
Genet Med. 2010 Apr;12(4 Suppl):S15-38
20393305
Nat Genet. 1993 Jul;4(3):289-94
7689389
Pediatrics. 2006 Oct;118(4):1357-70
17015524
Ment Retard Dev Disabil Res Rev. 2003;9(2):79-88
12784225
Pediatrics. 2000 Oct;106(4):798-817
11015525
Hum Mol Genet. 1997 Nov;6(12):2173-7
9336442
Curr Opin Pediatr. 2005 Dec;17(6):709-12
16282775
Ear Hear. 2006 Dec;27(6):732-41
17086082
Genet Med. 2007 Jul;9(7):413-26
17666888
Am J Hum Genet. 1998 Jan;62(1):27-35
9490575
Ear Hear. 2003 Aug;24(4):324-31
12923423
Nat Genet. 1997 Dec;17(4):411-22
9398842
Otol Neurotol. 2005 Jul;26(4):610-5
16015155
Hum Mutat. 2008 Feb;29(2):306-14
18161878
Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):231-6
17372079
Nature. 1997 May 1;387(6628):80-3
9139825
Genet Med. 2004 Nov-Dec;6(6):521-5
15545749
Genet Med. 2002 May-Jun;4(3):162-71
12180152
Hum Mutat. 1996;7(4):346-54
8723685
N Engl J Med. 2006 May 18;354(20):2151-64
16707752
Am J Hum Genet. 1998 Jan;62(1):15-9
9443888
Pediatrics. 2006 Sep;118(3):985-94
16950989
Genet Med. 2006 Dec;8(12):779-83
17172941
Int J Technol Assess Health Care. 2000 Autumn;16(4):1120-35
11155832
Genet Test. 2000;4(1):1-7
10794354
Otolaryngol Head Neck Surg. 2004 Dec;131(6):804-9
15577772
Genet Med. 2003 Jul-Aug;5(4):295-303
12865758
Am J Med Genet A. 2004 Sep 15;130A(1):17-21
15368489